BioSpace News Archive

Researchers Stumble Upon Potential Key to Slow DMD

Research scientists have found that a colony-stimulating factor 1 receptor inhibitor may also be a potential treatment for Duchenne muscular dystrophy.

July 5, 2022
·
2 min read
·
Tristan Manalac
Drug Development

Seagen, ANeuroTech Start July with a Clinical Bang

Seagen announced positive data from its Phase II trial in colorectal cancer, and the FDA provided positive feedback supporting a Phase IIIb trial for ANeuroTech’s MDD drug.

July 5, 2022
·
2 min read
·
Jazmine Colatriano M.S.
FDA

FDA Has Ways to Go to Keep Pace with 2020/21 Approvals

As the calendar pages continue to turn, the FDA has a slew of novel drugs awaiting approval, several of which are likely to become game-changers for patients and key assets for companies.

July 5, 2022
·
3 min read
·
Alex Keown
Drug Development

FDA Clears Vertex to Continue Dosing in Diabetes Cell Therapy Trial

The FDA lifted its clinical hold on Vertex Pharmaceuticals’ Phase I/II clinical trial of VX-880, a pancreatic islet cell replacement therapy for people with Type I Diabetes (TID).

July 5, 2022
·
2 min read
·
Hayley Shasteen
Biopharma Investment in China is Thriving Amid U.S. Downturn

Many healthcare, pharmaceutical and biotech companies continue to place their bets on China, bringing fresh rounds of investments to and forging new partnerships with local firms.

July 5, 2022
·
3 min read
·
Tristan Manalac
Drug Development

Follow-Up Data on Bayer’s Larotrectinib Hints at Potentially Curative Impact

BioSpace connected with Theodore Laetsch, M.D., lead investigator of the pediatric larotrectinib trial (SCOUT), to gain more insight into the drug, the trial and how patients’ lives are being affected.

July 5, 2022
·
4 min read
·
Abbey Glasure
Business

AstraZeneca Bolsters Blood Cancer Pipeline with $1.27B TeneoTwo Takeover

The transaction, expected to close in the third quarter of this year, includes TeneoTwo’s proposed drug for relapsed and refractory B-cell non-Hodgkin lymphoma TNB-486.

July 5, 2022
·
2 min read
·
Vanessa Doctor, RN
Policy

Activists Call for Over-the-Counter Access to Abortion Meds

Following the Supreme Court’s decision to overturn Roe v. Wade, abortion rights activists are calling for the FDA to consider making abortion medication Mifeprex an over-the-counter option for patients.

July 5, 2022
·
3 min read
·
Alex Keown
Drug Development

Dyne’s Exon-51 Skipping DMD Therapy Moves Forward on FDA Go Sign

The FDA lifted the clinical hold on Dyne Therapeutics’ clinical study of DYNE-251 in Duchenne muscular dystrophy (DMD) patients amenable to skipping exon 51. A Phase I/II trial is expected by mid-year.

July 5, 2022
·
3 min read
·
Mark Terry
Drug Development

Anebulo’s Cannabinoid Intoxication Reversal Agent Effective in Netherlands Study

The Phase II study, conducted in the Netherlands, evaluated the single-dose ANEB-001 in treating healthy participants affected by THC. Anebulo plans to file an IND with the FDA by the end of 2022.

July 5, 2022
·
2 min read
·
Vanessa Doctor, RN